[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Federal University of Minas Gerais\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":405},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,46,73,102,137,158,187,217,246,274,299,324,354,378],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100645028","impact-of-hmb-supplementation-on-inflammation-and-outcomes-in-head-and-neck-cancer-100645028",false,"NCT07675421","Impact of HMB Supplementation on Inflammation and Outcomes in Head and Neck Cancer","Impact of Beta Hydroxy Methyl Butyrate (HMB) Supplementation on Inflammatory Markers and Clinical Outcomes in Patients With Head And Neck Cancer","Inclusion Criteria:\n\n* Individuals aged 18 years or older;\n* Both sexes (male and female);\n* Patients treated at the outpatient clinic for head and neck carcinoma;\n* Indication for potentially curative tumor resection surgery.\n\nExclusion Criteria:\n\n* Diagnosis of cancer of the face, skin, paranasal sinuses, or thyroid;\n* Undergoing neoadjuvant or palliative treatment;\n* Cognitive or intellectual impairment that may hinder proper understanding of the study;\n* Refusal to participate or to sign the informed consent form.","ALL","18 Years",{"count":19,"type":20},66,"ESTIMATED","INTERVENTIONAL",[23],"NA","Cancer patients undergoing surgery are at high risk of malnutrition due to the effects of the tumor and surgical stress, which can lead to worse clinical outcomes. This study aims to evaluate the impact of beta-hydroxy-beta-methylbutyrate (HMB) supplementation on inflammatory markers and clinical outcomes in patients with malignant tumors of the upper airways and digestive tract undergoing surgery.\n\nThis is a randomized, double-blind clinical trial. Participants will be randomly assigned to one of two groups: intervention (3 g\u002Fday of HMB) or control (3 g\u002Fday of maltodextrin) for 30 days prior to surgery. Initial assessments will include nutritional status, muscle strength, quadriceps muscle thickness by ultrasound, and laboratory tests. Postoperative clinical outcomes will be monitored through electronic medical records.",[26],"Head and Neck Cancers",[28,29,30,31,32],"Head and Neck Neoplasms","Surgery","Inflammation","Muscle Mass","Postoperative Complications","RECRUITING","2026-06-26",{"date":36,"type":37},"2026-06-30","ACTUAL",{"date":39,"type":20},"2026-08-01",{"date":41,"type":20},"2027-11-30",{"name":43,"class":44},"Federal University of Minas Gerais","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100589118","effect-of-training-and-use-of-cane-on-gait-in-individuals-with-parkinsons-disease-100589118","NCT06950255","Effect of Training and Use of Cane on Gait in Individuals With Parkinson's Disease","Effect of a 3-week Program of Cane Training and Use on Gait of Individuals With Parkinson's Disease: Protocol for a Randomized Controlled Trial","Inclusion Criteria:\n\n* diagnosis of idiopathic PD confirmed by a neurologist\n* classification between stages II to IV of the modified Hoehn \\& Yahr Scale (HY)\n* use of anti-parkinsonian medication with stable pharmacological therapy for at least 6 months\n* ability to walk independently in a 14-meter corridor with a walking speed ≤ 1.1 m\u002Fs\n* ability to use a single-point cane during walking correctly and safely, and not being regular users of any type of assistive device since the diagnosis of PD.\n\nExclusion Criteria:\n\n* cognitive impairment, assessed by the Mini Mental State Examination\n* use deep brain stimulation,\n* had any other neurological, cardiopulmonary or musculoskeletal condition that may compromise the tests performance","40 Years",{"count":55,"type":20},26,[23],"Introduction: Although individuals with Parkinson's disease (PD) commonly use assistive devices, the effects of these devices on gait remain poorly understood. Furthermore, previous studies on this topic only investigated the immediate effects of device usage, and the investigated outcomes were predominately performance-based neglecting participant-centered outcomes.\n\nObjective: To investigate the effect of cane training and use on gait speed (primary outcome), gait confidence, cadence, step length, functional mobility, freezing of gait, fear of falls and satisfaction with the use of a cane (secondary outcomes) in individuals with PD.\n\nMethods: A double-blind, randomized controlled trial with intention-to-treat and per-protocol analysis will be carried out. A total of 26 individuals with PD will be recruited based on the following inclusion criteria: age ≥ 40 years, diagnosis of idiopathic PD, classification between stages II to IV on the modified Hoehn \\& Yahr Scale, stable use of anti-parkinsonian pharmacological therapy, ability to walk independently with a walking speed ≤ 1.1 m\u002Fs (defined to screen individuals with gait impairments), and ability to use a single-point cane during walking without regular use of any type of assistive device since the diagnosis of PD. Participant will be randomly divided into two groups that will receive: (1) cane training and use (experimental group) or (2) global stretches and health education (time and attention-controlled group). The intervention will be provided in four sessions lasting 40 minutes each, spaced over 15 to 22 days. Additionally, individuals will be instructed to use a cane (experimental group) or perform stretching exercises (time and attention-controlled group) daily, starting from the first day of training. Assessments will be conducted at the beginning of the study (week 0), post-intervention (after the 3-week intervention), and one month after the cessation of the intervention (8-week follow-up). The primary outcomes is gait speed. Secondary outcomes include gait confidence, cadence, step length, functional mobility, freezing of gait, fear of falls, and satisfaction with the use of a cane. Between-group differences will be measured using a two-way repeated measures ANOVA, considering baseline, post-intervention, and follow-up assessments, following both intention-to-treat and per-protocol approaches (α=0.05).\n\nConclusions: The results of the present study will provide information about the effects of cane training and use on the gait of individuals with PD who will have the opportunity to use the cane in their real-life context.",[59],"Parkinson Disease",[61,62,63,64],"assistive device","canes","mobility","gait","2026-06-09",{"date":67,"type":37},"2026-06-11",{"date":69,"type":37},"2025-05-01",{"date":71,"type":20},"2026-09-30",{"name":43,"class":44},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":45},"100615752","effect-of-a-nutritional-formula-composed-of-proteins-and-carbohydrates-on-gastric-emptying-in-elderly-individuals-100615752","NCT07296692","Effect of a Nutritional Formula Composed of Proteins and Carbohydrates on Gastric Emptying in Elderly Individuals","Effect of a Nutritional Formula Composed of Proteins and Carbohydrates on Gastric Emptying in Elderly Individuals: a Randomized, Crossover, Triple-blind Clinical Trial.","Inclusion Criteria:\n\n* Elderly individuals aged between 60 and 90 years\n* Non-smokers\n* No prior diagnosis of conditions that affect gastric emptying, such as:\n* Gastroesophageal reflux\n* Gastroparesis\n* Untreated Helicobacter pylori (H. pylori) infection\n* Stomach cancer\n* Esophageal cancer\n\nExclusion Criteria:\n\n* Volunteers who do not meet the inclusion criteria\n* Refusal to sign the informed consent form (ICF)\n* Volunteers with obesity (BMI over 35 kg\u002Fm²)\n* Volunteers who do not eat orally or have a prior diagnosis of delayed gastric emptying and are on routine use of prokinetic medications\n* Individuals diagnosed with Alzheimer's or Parkinson's disease",true,"60 Years","90 Years",{"count":84,"type":20},25,[23],"The objective of this clinical trial is to evaluate the effect of a nutritional formula composed of carbohydrates and proteins on gastric emptying in elderly individuals aged between 60 and 90 years. The main questions this study aims to answer are:\n\n* Does the nutritional formula composed of carbohydrates and proteins delay gastric emptying when compared to a formula composed only of carbohydrates?\n* Does the formula composed of carbohydrates and proteins cause gastrointestinal symptoms in the study population?\n\nThe researchers will compare both formulas (carbohydrates and proteins vs. carbohydrates only) to answer the main question.\n\nParticipants will be required to:\n\n* Attend the Nuclear Medicine Department after an 8-hour fast, on two separate days with a minimum interval of seven days for scintigraphy procedures.\n* Consume the offered formula in a randomized and blinded manner.\n* Report any gastrointestinal symptoms and complete visual analog scales for sensations such as hunger, satiety, and desire to eat.",[88],"Gastric Emptying",[90,91,92,93],"proteíns","elderly","gastric emptying","scintigraphy","2026-04-29",{"date":96,"type":37},"2026-05-05",{"date":98,"type":37},"2026-02-21",{"date":100,"type":20},"2027-05",{"name":43,"class":44},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":109,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":124,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":45},"100629899","aromatherapy-for-mental-health-promotion-in-ivf-patients-100629899","NCT07480668","Aromatherapy for Mental Health Promotion in IVF Patients","Aromatherapy for Mental Health Promotion in In Vitro Fertilization Patients: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Female gender, age over 18 years.\n* Diagnosis of infertility with indication for In Vitro Fertilization (IVF).\n* Patients on the waiting list at HC-UFMG.\n* Agreement not to practice other mind-body or herbal complementary therapies during the study.\n* DASS-21 screening score compatible with at least mild anxiety, stress, and\u002For depression.\n* No aversion to inhaling essential oil or synthetic lavender essence.\n\nExclusion Criteria:\n\n* Severe neurological, psychiatric, or clinical disorders (e.g., schizophrenia, severe depression) that prevent participation.\n* Use of medications that could confound the primary outcome (e.g., sleep medications, anxiolytics, antidepressants, neuroleptics) in the 30 days prior to or during the study.\n* Known allergy to lavender products.\n* Pregnancy during the study period.\n* Use of essential oils in the last 90 days.","FEMALE",{"count":111,"type":20},120,[23],"The experience of infertility can cause significant emotional instability, especially for patients awaiting In Vitro Fertilization (IVF) treatment, generating anxiety, stress, and depressive symptoms. This study is a randomized clinical trial assessing the effectiveness of aromatherapy in improving mental health and quality of life in women undergoing infertility treatment. 120 participants will be randomized into three groups (Intervention, Placebo, and Control). The intervention involves the inhalation of true lavender essential oil (Lavandula angustifolia) for four weeks.",[115,116,117,118,119,120,121,122,123],"Anxiety","Stress","Depression Disorder","Quality of Life","Aromatherapy","IVF","Complementary Therapies","Spirituality","Infertility",[125,119,126,127,122,120,115,116,128,129],"Infertility, Female","Lavender Oil","Complementary Therapy","Depression","In Vitro Fertilization","2026-04-24",{"date":94,"type":37},{"date":133,"type":37},"2026-03-01",{"date":135,"type":20},"2026-12",{"name":43,"class":44},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":109,"minAge":17,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":45},"100608509","chronic-ingestion-of-fructooligosaccharide-and-psyllium-on-intestinal-transit-in-women-with-functional-constipation-a-randomized-crossover-trial-100608509","NCT07202481","Chronic Ingestion of Fructooligosaccharide and Psyllium on Intestinal Transit in Women With Functional Constipation: A Randomized Crossover Trial","Effects of Chronic Ingestion of Fructooligosaccharide and Psyllium on Intestinal Transit Time in Women Diagnosed With Functional Constipation: A Randomized, Crossover, Double-Blind Clinical Trial","Inclusion Criteria\n\n* Female participants aged 18-59 years.\n* Willingness to sign the Informed Consent Form .\n* No restrictions on the consumption of egg or gluten.\n* No history or diagnosis of gastrointestinal diseases other than functional constipation.\n* Non-smokers.\n* No use of prebiotics, probiotics, synbiotics, or antibiotics at least 10 days prior to the study.\n* No previous surgery affecting gastrointestinal transit.\n* Willingness to discontinue the use of laxatives at least 4 days prior to scintigraphic imaging.\n* Participants who do not consume adequate dietary fiber (25-30 g\u002Fday) as assessed by dietary recall.\n* No confirmed or suspected pregnancy during the study.\n* No self-reported menopause\n\nExclusion Criteria\n\n* Diagnosis of diabetes, severe hyperthyroidism, or hypothyroidism.\n* Use of opioid medications.\n* Delayed gastric emptying at 4 hours during the placebo period (participants meeting this criterion will be excluded from final analysis).","59 Years",{"count":84,"type":20},[23],"The goal of this clinical trial is to evaluate the effect of dietary fibers in the treatment of functional constipation in women. It will also assess the potential side effects associated with fiber consumption. The main questions it aims to answer are:\n\n* In women with constipation who do not consume adequate dietary fiber, does supplementation help improve bowel function?\n* Among the fibers studied, is there any hierarchy of effect in the treatment of constipation (i.e., is one more effective than the other)?\n\nThe researchers will compare the effects of the two dietary fibers against each other and against a control to evaluate their impact.\n\nParticipants will:\n\n* Consume 20 g of fiber daily for 6 days, divided into two doses of 10 g each.\n* Attend a nuclear medicine visit at the end of each 6-day fiber period to perform scintigraphy.\n* Keep a daily record of bowel habits and dietary intake.",[149],"Constipation - Functional","2026-03-21",{"date":152,"type":37},"2026-03-24",{"date":154,"type":37},"2026-03-14",{"date":156,"type":20},"2027-12",{"name":43,"class":44},{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":166,"maxAge":17,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":45},"100586562","modified-and-context-focused-sports-intervention-in-adolescents-with-autism-study-protocol-100586562","NCT06916988","Modified and Context-Focused Sports Intervention in Adolescents With Autism: Study Protocol","Modified Sports Intervention Combined With Context-Focused Intervention in Adolescents With Autism Spectrum Disorder: Protocol for a Mixed Methods Study","ASD","Inclusion Criteria:\n\n* Diagnosis of Autism Spectrum Disorder (ASD).\n* Level I of functioning (able to maintain interaction and adapt to changes).\n* Level II of functioning (able to communicate with others but faces difficulties when changes occur) according to the Autism Spectrum Disorder Social Communication Functioning Classification System.\n\nExclusion Criteria:\n\n* Cognitive limitations\n* Behavioral limitations\n* Clinical limitations (e.g., severe cardiorespiratory disease)","12 Years",{"count":168,"type":20},52,[23],"Adolescents with Autism Spectrum Disorder (ASD) typically engage less in physical activities than their typically developing peers, influenced by intrinsic and extrinsic factors. Modified sports interventions, like Sports Stars Brazil, can improve motor skills and promote lifelong participation in sports by enhancing physical, social, and cognitive abilities. However, adolescents often face barriers to engaging in community sports and recreational activities after completing the program. PREP is an approach designed to address these barriers by modifying environments and empowering families. To date, no study has explored this combination in adolescents with ASD. Objective: This protocol assesses the effectiveness of combining Sports Stars Brazil with PREP to enhance participation and physical literacy in adolescents with ASD and explores participant and family perceptions. Method: A mixed-methods study with two phases: 1) a randomized controlled trial to investigate combined intervention's effects; and 2) evaluation of participant and family perceptions.",[172],"Autism Spectrum Disorder (ASD)",[174,175,176,177,178],"Context-centered intervention","Participation","Adolescents","Modified Sports","Autism Spectrum Disorder","2026-03-12",{"date":181,"type":37},"2026-03-13",{"date":183,"type":37},"2025-06-01",{"date":185,"type":20},"2027-06-01",{"name":43,"class":44},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":197,"briefSummary":198,"conditions":199,"keywords":202,"overallStatus":208,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":4},"100606717","evaluation-of-clinical-intelligence-support-to-reduce-errors-in-normal-ecgs-100606717","NCT07179185","Evaluation of Clinical Intelligence Support to Reduce Errors in Normal ECGs","PRECISE-ECG: Prospective Randomized Evaluation of Clinical Intelligence Support to Reduce Errors in Normal ECGs","PRECISE-ECG","Inclusion Criteria:\n\n* ECGs performed routinely by the Rede de Telemedicina de Minas Gerais (RTMG)\n\nExclusion Criteria:\n\n* ECGs from patients younger than 18 years",{"count":196,"type":20},710,[23],"This study will evaluate the performance of specialist physicians in interpreting normal electrocardiograms (ECGs) with and without the assistance of an artificial intelligence (AI) neural network. The primary aim is to determine whether AI support affects the rate of false-positive interpretations of normal tracings. Secondary aims include evaluating the time required for interpretation, the sensitivity for detecting abnormalities, and the effect on false positives in ECGs with major abnormalities according to the Minnesota Code system. All ECGs in the sample will be reviewed by a panel of three specialists, to determine the reference classification.",[200,201],"Electrocardiogram","Cardiovascular Abnormalities",[203,204,205,206,207],"artificial intelligence","electrocardiography","diagnostic methods","telemedicine","normal electrocardiogram","NOT_YET_RECRUITING","2025-09-16",{"date":211,"type":37},"2025-09-22",{"date":213,"type":20},"2025-10-01",{"date":215,"type":20},"2025-11",{"name":43,"class":44},{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":80,"sex":16,"minAge":17,"maxAge":144,"enrollmentInfo":225,"targetDuration":4,"studyType":21,"phases":227,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":208,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":45},"100606220","phase-1-clinical-trial-to-evaluate-the-safety-and-immunogenicity-of-the-vivaxin-vaccine-for-malaria-caused-by-plasmodium-vivax-100606220","NCT07172724","Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax.\"","\"First-in-human, Phase 1, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax.\"","Vivaxin-001","Inclusion Criteria:\n\n1. Non-pregnant women and men aged between 18 and 59 years;\n2. Willingness to participate in the study and undergo all study procedures, as demonstrated by signing the informed consent form (ICF);\n3. In good general health, as determined by medical examination;\n4. Women of childbearing potential must agree to use an acceptable\\* contraceptive method for at least 30 days prior to the first vaccination and for at least 6 months following administration of the first dose of the investigational product, ensuring at least 3 months after the final vaccine dose have elapsed;\n5. Agreement not to donate blood during the course of study participation.\n\n   * Acceptable contraceptive methods:\n\n     * Barrier methods, including condom or cervical cap;\n     * Surgically sterile partner\u002Fparticipant (including those who have undergone vasectomy, hysterectomy, bilateral oophorectomy, and\u002For tubal ligation) who is the sole sexual partner;\n     * Intrauterine device (with or without hormones);\n     * Hormonal birth control methods (oral, topical, injectable, or implantable);\n     * True sexual abstinence that is consistent with the participant's preferred and usual lifestyle.\n\nNote: Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) or withdrawal (coitus interruptus) will not be considered acceptable methods.\n\nExclusion Criteria:\n\n1. Prior history of malaria infection confirmed by serological testing;\n2. Prior history of malaria vaccination;\n3. Intention to travel to a malaria-endemic area during the study period;\n4. Pregnant or breastfeeding women, or those intending to become pregnant or breastfeed within the first 6 months of the study;\n5. Evidence of clinically active disease, such as but not limited to: neurological, renal, cardiovascular, endocrine, pulmonary, hepatic, hematological, immunological, neoplastic, or infectious diseases;\n6. Use of concomitant medication for control of an underlying medical condition;\n7. Positive serological test for HBV, HCV, or HIV;\n8. Any condition that, in the opinion of the study investigator, could pose a risk to the participant or confound the study results, including clinically stable chronic conditions such as diabetes, hypertension, or neuralgias, among others;\n9. Psychiatric illness or cognitive impairment that, in the opinion of the investigator, may affect the participant's ability to comply with the clinical study schedule;\n10. History of alcohol or substance abuse within 12 months prior to enrollment that resulted in family, medical, or occupational problems;\n11. History of severe allergic reaction or anaphylaxis to any component of the vaccine;\n12. History of asplenia;\n13. Participation in any other investigational clinical trial within 12 months prior to inclusion in this study;\n14. Plans to participate in other clinical trials concurrently with this study;\n15. Use of any immunosuppressive therapy within 3 months prior to enrollment or plans to use such therapy within 3 months after vaccination, including corticosteroids or other immunosuppressive drugs. An immunosuppressive dose of corticosteroid is defined as the equivalent of 20 mg\u002Fday of prednisone for more than one week. Topical or nasal corticosteroids are not considered immunosuppressive;\n16. Use of blood products (including blood or immunoglobulins) within 3 months prior to enrollment in this study, or plans to use them during the study period;\n17. Suspected or confirmed fever (axillary temperature ≥ 37.8 °C) within 72 hours prior to study enrollment. Enrollment should be postponed until the participant has been afebrile for at least 72 hours;\n18. Receipt of any live attenuated or inactivated vaccine within 28 or 14 days, respectively, prior to administration of the investigational product, or plans for immunization within 28 days after enrollment in the study.",{"count":226,"type":20},48,[228],"PHASE1","Phase 1 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of a malaria vaccine named Vivaxin against the protozoan Plamodium vivax in participants with no prior malaria infection",[231],"Malaria Vivax",[233,234,235,236,237],"vaccine","malaria","Plasmodium vivax","prevention","malaria vivax","2025-09-08",{"date":240,"type":37},"2025-09-15",{"date":242,"type":20},"2025-09",{"date":244,"type":20},"2027-06",{"name":43,"class":44},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":21,"phases":256,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":208,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":273},"100586563","phase-2-clinical-trial-evaluating-safety-and-efficacy-of-resomelagon-on-dengue-infection-resovir-2-100586563","NCT06917001","Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)","A Randomized, Double-blind, Placebo-controled, Phase 2a Trial Evaluating the Safety and Initial Efficacy of Resomelagon in Patients With Dengue Infection","RESOVIR-2","Inclusion Criteria:\n\n* Patients who are 18 to 65 years old;\n* Able to understand study procedures and give informed consent;\n* Presents with more than 36 and less than 84h since symptoms onset;\n* Symptoms compatible with dengue infection (fever, myalgia, arthralgia, headache or conjunctivitis) with positive antigen test or polymerase chain reaction test.\n\nExclusion Criteria:\n\n* Has any comorbidity which is perceived as significant by the investigator;\n* Significant laboratory abnormalities discovered at triage: Hemoglobin \\\u003C10g\u002FdL; Platelet count \\\u003C 50.000\u002FmicroL; alanine transaminase \\> 3x upper limit of normal; Total bilirubin \\>1,5 x upper limit of normal; glomerular filtration rate \\\u003C 60mls\u002Fmin\u002F1,73m2;\n* Contraindications or known hypersensitivity to Resomelagon;\n* Presents as dengue with warning signs or severe dengue at inclusion;\n* Currently participating in another drug clinical trial;\n* Clinical evidence of another infection that might explain current symptoms;\n* Pregnant women or women actively trying to achieve pregnancy.","65 Years",{"count":111,"type":20},[257],"PHASE2","The goal of this clinical trial is to understand if Resomelagon can treat adult patients with Dengue virus infection. The main questions the investigators aim to answer are:\n\nIs Resomelagon safe to use in patients with Dengue? Is Resomelagon able to reduce the duration of illness? (defined by clinical and laboratory criteria) Participants will be allocated to Resomelagon or placebo groups in this study and asked to take the medication and submitted to blood tests.",[260],"Dengue Fever",[262,263,264,265,252],"Resomelagon","Resolution of inflammation","Melanocortin","Dengue","2025-08-27",{"date":268,"type":37},"2025-08-28",{"date":270,"type":20},"2026-02",{"date":156,"type":20},{"name":43,"class":44},2,{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":21,"phases":283,"briefSummary":284,"conditions":285,"keywords":287,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":296,"leadSponsor":298,"locationsCount":45},"100602095","brazilian-adaptation-of-an-intervention-developed-in-ireland-to-promote-healthy-lifestyle-behaviors-post-stroke-a-feasibility-study-100602095","NCT07119047","Brazilian Adaptation of an Intervention Developed in Ireland to Promote Healthy Lifestyle Behaviors Post-stroke: a Feasibility Study","Brazilian Adaptation of an Intervention Developed in Ireland to Promote Healthy Lifestyle Behaviors Post-stroke: Protocol for a Feasibility Study","Inclusion Criteria:\n\n* Clinical diagnosis of subacute or chronic stroke;\n* Age ≥ 18 years;\n* Discharged from hospital and living in the community;\n* Self-identified need to change at least one of the following lifestyle-related behaviors: physical inactivity, unhealthy diet, smoking, harmful alcohol use, or non-adherence to prescribed medication.\n\nExclusion Criteria:\n\n* Positive screening test for possible cognitive alterations;\n* Pain or other adverse health conditions that compromise the performance of the proposed intervention program, such as vestibular disorders, severe arthritis, or any other diagnosed disease of the nervous system;\n* Presence of comprehensive and\u002For expressive aphasia.",{"count":282,"type":20},10,[23],"Introduction: Low- and middle-income countries, such as Brazil, are most impacted by the high burden of recurrent stroke. These countries also lack structured interventions to promote the adoption of healthy lifestyle behaviors in the context of stroke secondary prevention. In contrast, high-income countries, such as Ireland, which invest more in research, have more advanced studies on this topic. However, before implementing interventions developed in countries like Ireland in middle-income countries like Brazil, it is necessary to adapt them to account for cultural and socioeconomic differences. Furthermore, once the adaptation is made, it is essential to investigate the feasibility of implementing the intervention in the new context.\n\nObjective: To investigate the feasibility of implementing the Brazilian adaptation of the Irish intervention \"iHELP Stroke: Improving Health and Lifestyle Programme\", which aims to promote the adoption of healthy lifestyle behaviors post-stroke.\n\nMethodology: This is a phase 1 interventional feasibility study, using a pre- and post-intervention design, to be conducted with ten individuals post-stroke, residing in Belo Horizonte, MG, Brazil. The intervention will consist of eight sessions: one educational session, one individual session, and six group sessions, held weekly. The outcomes of interest will include feasibility (recruitment, intervention, and measurement) and clinical outcomes (achievement of the main goal defined by the participants and the number\u002Fproportion of participants who meet this goal). Descriptive statistics will be used for analysis.\n\nConclusions: The results of this feasibility study will provide valuable insights for designing subsequent phases of a clinical trial.",[286],"Stroke",[286,288,289,290,291],"Healthy Lifestyle","Feasibility Study","Clinical Trial","Secondary Prevention","2025-08-11",{"date":294,"type":37},"2025-08-12",{"date":69,"type":37},{"date":297,"type":20},"2025-10",{"name":43,"class":44},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":80,"sex":109,"minAge":17,"maxAge":144,"enrollmentInfo":306,"targetDuration":4,"studyType":21,"phases":308,"briefSummary":309,"conditions":310,"keywords":312,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":323,"locationsCount":273},"100329813","chronic-effect-of-fasting-100329813","NCT03574103","Chronic Effect of Fasting","Comparison of Weight Loss Induced by Daily Time-Restricted Feeding Versus Daily Caloric Restriction in Women With Overweight and Obesity","Inclusion Criteria:\n\n* Females;\n* Aged between 18 and 59 years old;\n* Body mass index equal or greater 25 kg\u002Fm²;\n* Agree to sign the informed consent.\n\nExclusion Criteria:\n\n* Any chronic health conditions (e.g. chronic renal failure, autoimmune, heart, and liver disease);\n* Thyroid diseases or medications for its treatment;\n* Medications known to affect total energy expenditure;\n* Use of steroids, immunosuppressants or non-steroidal anti-inflammatory drugs, weight-loss medications, oral hypoglycemic agents or insulin and any medications that influence metabolic and\u002For inflammatory parameters;\n* Previous surgery for weight loss;\n* Pregnancy or breast-feeding;\n* Smoking;\n* Alcohol use (\\>2 doses\u002Fday).",{"count":307,"type":20},45,[23],"The aim of the study is to determine if time-restricted feeding (TRF) is an effective dietary strategy to weight loss after 8 weeks intervention. TRF will be compared with an intervention without restriction in time for feeding. Both strategies will be with caloric restriction.",[311],"Overweight and Obesity",[313,314,315,316],"Obesity","Overweight","Weight loss","Fasting","2025-03-14",{"date":319,"type":37},"2025-03-18",{"date":321,"type":37},"2018-07-09",{"date":135,"type":20},{"name":43,"class":44},{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":332,"targetDuration":4,"studyType":21,"phases":334,"briefSummary":335,"conditions":336,"keywords":341,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":45},"100512492","yoga-for-patients-with-chronic-back-pain-and-poor-prognosis-100512492","NCT05953155","YOga for Patients with Chronic BACK Pain and Poor PROgnosis","Effectiveness of YOga in Patients with Chronic Low BACK Pain and Poor PROgnosis (YOBACK-PRO Trial): a Randomized Controlled Trial","YOBACK-PRO","Inclusion Criteria:\n\n* report chronic nonspecific LBP, defined as pain and discomfort localized below the costal margin and above the inferior gluteal folds, with or without leg pain and of at least 3 months' duration.\n* score ≥ 50 points (out of 100) in the Orebro Musculoskeletal Pain Questionnaire.\n* have an average back pain intensity of 3 points or more on a 0-10 numerical pain rating scale.\n\nExclusion Criteria:\n\n* serious spine pathology (e.g. tumors, fractures, and inflammatory diseases).\n* nerve root compromise (i.e. at least 2 of the following signs: weakness, reflex change, or sensation loss associated with the same spinal nerve).\n* previos spinal surgery.\n* pregnancy or having given birth within the previous 3 months.\n* any medical condition that prevented being physically active (e.g., serious cardiovascular, kidney or neurological diseases).\n* any other musculoskeletal condition that may affect activity and movement participation in a Yoga program during the last year.\n* not currently receiving other physical activity-based intervention (e.g., Pilates, physical therapy, aquatic exercise).\n* inadequate Portuguese literacy for the study's questionnaires and instructions.",{"count":333,"type":20},110,[23],"The goal of this clinical trial is to investigate the effectiveness of yoga for patients with chronic low back pain and high risk of poor prognosis. The main question it aims to answer is:\n\n\\- In patients with back pain and high risk of poor prognosis, what is the effectiveness of yoga plus education on reducing pain and disability compared to a control group receiving education alone?\n\nA total of 110 patients with chronic low back pain and classified as high risk of poor prognosis according to the Orebro Musculoskeletal Pain Screening Questionnaire (i.e. score ≥ 50 points out of 100) will be recruited for this study. Participants will be randomized into two groups: yoga and control. The yoga group will receive a 3-month course of yoga program consisting of two sessions per week and 3 educational classes. The control group will receive 3 educational classes over a 12-week period. Outcome measures will be assessed at baseline, at post-intervention (i.e. 3-months post randomization) and at 6-month follow up (i.e. 6-months post randomization).",[337,338,339,340],"Low Back Pain","Chronic Low-back Pain","Back Pain","Back Pain Lower Back Chronic",[342,343,344,345],"low back pain","chronic low back pain","yoga","poor prognosis","2025-03-13",{"date":348,"type":37},"2025-03-17",{"date":350,"type":37},"2023-07-27",{"date":352,"type":20},"2027-07-30",{"name":43,"class":44},{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":21,"phases":363,"briefSummary":364,"conditions":365,"keywords":366,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":45},"100521318","telehealth-intervention-involving-hearts-technical-package-and-activity-monitor-to-promote-physical-activity-post-stroke-100521318","NCT06068036","Telehealth Intervention Involving HEARTS Technical Package and Activity Monitor to Promote Physical Activity Post-stroke","Telehealth Intervention Involving the HEARTS Technical Package and the Use of an Activity Monitor to Increase Physical Activity Level Post-stroke: a Feasibility Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosis of stroke for more than six months;\n* ≥18 years of age;\n* Be rated as \"Inactive\" according to Human Activity Profile (HAP);\n* Provide medical approval to practice physical activity.\n\nExclusion Criteria:\n\n* Positive screening test for possible cognitive alterations;\n* Pain or other adverse health condition that compromises the performance of the proposed intervention program, such as vestibular disorders, severe arthritis or any other diagnosis of disease of the nervous system.",{"count":362,"type":20},24,[23],"Objectives: The aim of this feasibility randomized controlled trial (RCT) study is to investigate whether the theoretically informed telehealth intervention involving the HEARTS Technical Package and the use of an activity monitor to increase physical activity level post-stroke is feasible and to estimate the parameters for conducting a fully powered RCT.\n\nDesign: A Phase 1 feasibility RCT study with blinded assessment will assign eligible participants to experimental or control group. Participants in both groups will undergo a theoretically informed telehealth intervention based on the HEARTS technical package (a face-to-face session and telephone call follow-up). The experimental group will have additional use of the Mi Band 7® Smartwatch activity monitor. For both groups, the intervention will last for 12 weeks. The feasibility outcomes will be identified considering the different phases of conducting the study. A trained researcher, blinded to the group allocation, will collect the sociodemographic, anthropometric, and clinical outcomes, in a university laboratory setting.\n\nStudy Outcomes: Feasibility of recruitment, intervention, and measurement, and clinical outcomes.\n\nConclusions: Results from this feasibility RCT study will inform on the design and sample required for a fully powered RCT with a similar aim.",[286],[286,367,368,289,369],"Physical activity","Telehealth","Randomized controlled trial","2025-02-25",{"date":372,"type":37},"2025-02-27",{"date":374,"type":37},"2023-09-27",{"date":376,"type":20},"2025-07",{"name":43,"class":44},{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":21,"phases":387,"briefSummary":388,"conditions":389,"keywords":391,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":45},"100560426","effect-of-synbiotic-supplementation-on-the-prevention-of-mucositis-in-cancer-patients-undergoing-chemotherapy-100560426","NCT06576986","Effect of Synbiotic Supplementation on the Prevention of Mucositis in Cancer Patients Undergoing Chemotherapy","Effect of Synbiotic Supplementation on the Prevention of Mucositis in Cancer Patients Undergoing Chemotherapy: Randomized, Double-masked, Parallel, Single-center Clinical Trial","Inclusion Criteria:\n\n* Colorectal tumor in the first oncological treatment\n* Age over 18 years old\n* Both sexes\n* Eligible for protocol with capecitabine alone or associated with oxaliplatin\n* Patients WITHOUT colostomy or WITH colostomy in the transverse\u002Fdescending\u002Fsigmoid region\n* Patient undergoing Radiotherapy treatment associated with Chemotherapy\n* Patients residing in Belo Horizonte and the metropolitan region\n* Patients who Accept and sign the Informed Consent Form (TCLE)\n\nExclusion Criteria:\n\n* Diagnosis of gastrointestinal carcinoid and stromal tumor (GIST)\n* Patients with Ileostomy\n* Patients with colostomy in the ascending region of the colon\n* Inflammatory bowel diseases: Crohn's and Colitis\n* Use of antibiotics and antifungals in the last 15 days\n* Use of prebiotic\u002Fprobiotic and\u002For synbiotic in the last 15 days\n* Use of antidiarrheal medication in the last 15 days\n* Presence of fever and mucus discharge\n* Pregnant or breastfeeding women\n* Patients who refuse to participate in the study.",{"count":386,"type":20},80,[23],"Introduction: In the 2023-2025 period, colorectal cancer (CRC) will be the third most common type of cancer in Brazil. The most commonly used therapeutic approaches are chemotherapy (QTx) and radiotherapy (RTx). QTx agents, such as capecitabine, affect both malignant cells and normal cells such as gastrointestinal, capillary and immune cells. Cellular damage in the gastrointestinal tract (GIT) results in various symptoms, such as mucositis and diarrhea. Diarrhea is linked to mucosal damage and can result in dehydration, malnutrition and hospitalization, leading to cardiovascular complications and death. Mucositis is inflammation that affects the GIT. This condition makes treatment difficult, leading to reductions, delays or interruption of QTx. These scenarios harm the patient's prognosis and quality of life, resulting in high costs for symptom control, nutritional assistance, management of secondary infections and hospitalization. The Mucositis Study Group (MASCC\u002FISOO) guidelines recommend the use of probiotics as a preventive measure against diarrhea in cancer patients undergoing QTx and\u002For RTx. However, the safety of using probiotics in immunosuppressed patients is still controversial and hypotheses are based on epidemiological and experimental studies. This makes it necessary to evaluate whether supplementation with pro- or synbiotics before chemotherapy would have the same beneficial results. Objective: To evaluate the effect of synbiotic supplementation on the prevention, incidence and severity of mucositis in cancer patients undergoing QTx. Method: This is a single-center parallel double-masked randomized clinical trial to be carried out at the Borges da Costa\u002FUFMG Outpatient Clinic at Hospital das Clínicas in Belo Horizonte - Minas Gerais (HC-BH\u002FMG). The inclusion criteria are patients diagnosed with CRC eligible for first-line treatment with Capecitabine, aged ≥ 18 years, both sexes, signed the informed consent form. The study was approved by CEP-UFMG. Expected results: It is expected that supplementation with synbiotics in the pre-QTx period will promote modulation of the microbiota and strengthening of the intestinal barrier, resulting in a lower incidence and severity of mucositis and diarrhea, improving the quality of life of these patients.",[390],"Colo-rectal Cancer",[392,393,394,395,396],"colorectal cancer","symbiotic","Mucositis","diarrhea","chemotherapy","2024-08-27",{"date":399,"type":37},"2024-08-29",{"date":401,"type":37},"2023-12-12",{"date":403,"type":20},"2026-12-12",{"name":43,"class":44},""]